Methodist Health System

Quick facts

Phase 2 pipeline

• Anti-MRSA therapy · Infectious Diseases
  Targets bacterial cell wall synthesis to inhibit MRSA growth.
• antimetabolite · Metabolic
• differing IV antibiotic treatment
• IV antibiotic treatment from prior
• Moderna COVID-19 mRNA vaccine
• Pfizer COVID-19 mRNA vaccine · Infectious Disease
  mRNA vaccine that encodes for the SARS-CoV-2 spike protein
• pneumoniae bacteremia therapy
• PSMA radionuclide therapy
• Relistor Injectable Product

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Methodist Health System portfolio CI brief
• Methodist Health System pipeline updates RSS